{
  "extraction_metadata": {
    "timestamp": "2025-09-05T13:36:46.053652",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 4,
    "total_picos": 49
  },
  "picos_by_country": {
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 12,
      "ContextTokens": 3288
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy (dosectaxel or pemetrexed)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "EGFR inhibitors in patients who have not received these medicines in the first line",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "osymertinib in patients previously treated with first or second generation EGFR blockers",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ALK inhibitors if ALK gene rearrangement",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunity (nivolumab or atezolizumab)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "palliative radiotherapy",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "symptomatic progression",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "Sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel (DOC)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "Sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetexel (NIN+DOC)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "Sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed (XPM)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with generalised non-small cell lung cancer depends on the clinico-pathomorphological characteristics, the effects of prior systemic therapy, and the molecular characteristics of the tumour",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP and the KRAS mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP and the KRAS mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetaxel",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP and the KRAS mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "two-drug platinum-derived chemotherapy (P-CTH)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP and the KRAS mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed (PMX)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy (dosectaxel or pemetrexed)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "EGFR inhibitors in patients who have not received these medicines in the first line",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "osymertinib in patients previously treated with first or second generation EGFR blockers",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ALK inhibitors if ALK gene rearrangement",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunity (nivolumab or atezolizumab)",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "palliative radiotherapy",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "symptomatic progression",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients not previously treated with immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        },
        {
          "Population": "patients not previously treated with immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, with subgroup data by ECOG status), overall response rate (ORR; SOT 28% vs DOC 13%, RR [95% CI]=2.12 [1.35, 3.33]), disease control rate (DCR; SOT 83% vs DOC group), overall survival (OS; median OS 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100, no statistically significant differences between therapies in CodeBreaK 200), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with details on functional and symptom domains), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), safety outcomes (adverse events [AEs] including frequency and severity: treatment-related AEs in 65% of patients, grade ≥3 AEs in 23%, discontinuations due to AEs in 7%, dose modifications due to AEs in 26%, treatment-related death in 1%; specific AEs ≥10%: diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, increased asparagine aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, fever), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for SOT vs DOC), economic outcomes (incremental cost-utility ratio [ICUR] from the public payer perspective), and budget impact analysis."
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10268
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and except in cases of predominantly squamous histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and adenocarcinoma histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (defined as time from randomisation to death from any cause), symptomatology (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, and EQ-5D VAS), health-related quality of life (no assessable data), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific adverse events (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis [AE], peripheral oedema [AE], peripheral neuropathy [AE], alopecia [AE], blood and lymphatic system disorders [AE], fatigue [AE], fever [AE], infections and infestations [AE])"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10591
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, and 12-month Kaplan-Meier estimates reported), progression-free survival (PFS; median, hazard ratio, and 12-month assessment reported), objective response rate (ORR; RECIST v1.1, with specific percentages and confidence intervals), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (with hazard ratio and mean change from baseline to week 12), physical functioning (time to deterioration), quality of life (overall health status/quality of life, stability or deterioration reported), adverse event rate (using CTCAE v5), rate of Grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10908
    }
  }
}